新辅助化疗对晚期乳腺癌的影响  

The Effect of Neoadjuvant Chemotherapy for Advanced Breast Cancer

作　　者：李宏江[1] 敬静[1] 汪静[1] 吕青[1] 赵扬冰[1] 

机构地区：[1]四川大学华西医院普外一科,成都市610041

出　　处：《中国肿瘤临床》2006年第3期157-159,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨新辅助化疗是否能提高晚期乳腺癌患者的远期生存率。方法:对142例Ⅲb、Ⅳ期乳腺癌的临床资料进行总结。结果:新辅助化疗的75例中13例CR,其中5例达到病理完全缓解(pCR),44例PR。52例(69.3%)获得根治性手术(其中16例为Ⅳ期患者),2年总生存率为76.0%,无瘤生存率为48.0%。而未做术前化疗的67例中35例(52.2%)获得根治性手术,2年总生存率为56.7%,无瘤生存率为29.9%。结论:新辅助化疗能降低乳腺癌的术前TNM分期,并使部分Ⅳ期患者重新获得根治性手术的机会,并且能够改善晚期患者的生存率。Objective： To discuss whether neoadjuvant chemotherapy could increase the survival rate of patients with advanced-stage breast carcinoma Methods： Clinic data of 142 patients with advanced breast carcinoma was summarized, and all patients were followed up. Results： Of the 75 patients who had received preoperative chemotherapy, there was complete response （CR） patients 13 （17.3%）, including 5 （6.7%） patients with pathological complete response （pCR）, 44 （58.7%） with partial response （PR）, 12 （16.0%） with stable disease （SD）, and 52 patients were treated with radical surgery, including 16 with stage-Ⅳ breast cancer. The two-year overall survival （OS） was 76.0% （57/ 75） and relapse-free survival （RFS） was 48.0% （36/75）. On the other hand, of the other patients who had not received preoperative chemotherapy, 35 （52.2%） of them were treated with radical surgery. The two-year OS was 56.7% （38/67） （χ^2=5.9, P〈0.05） and RFS was 29.9% （20/67） （χ^2=4.9, P〈0.05）. Conclusion： Preoperative chemotherapy could decrease the TNM stage and part of the stage-Ⅳ patients can be treated by radical surgery. It will benefit the survival of patients with advanced breast cancer.

关 键 词：TNM分期 新辅助化疗 乳腺癌 外科治疗 

分 类 号：R737.9[医药卫生—肿瘤]